Cargando…
Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalisations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5 and XBB transmission
OBJECTIVES: Real-world data on continued effectiveness of nirmatrelvir/ritonavir against hospitalisation and severe COVID-19 in the context of widespread booster mRNA vaccine uptake and more immune-evasive Omicron subvariants is lacking. We conducted a retrospective cohort study in adult Singaporean...
Autores principales: | Wee, Liang En, Tay, An Ting, Chiew, Calvin, Young, Barnaby Edward, Wong, Betty, Lim, Ruth, Lee, Ching Li, Tan, Joyce, Vasoo, Shawn, Lye, David Chien, Tan, Kelvin Bryan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275656/ https://www.ncbi.nlm.nih.gov/pubmed/37331509 http://dx.doi.org/10.1016/j.cmi.2023.06.016 |
Ejemplares similares
-
Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study
por: Tan, Celine Y, et al.
Publicado: (2023) -
Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022) -
Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022) -
Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants
por: Wong, Carlos K H, et al.
Publicado: (2023) -
Vaccine effectiveness against Delta, Omicron BA.1, and BA.2 in a highly vaccinated Asian setting: a test-negative design study
por: Tan, Celine Y., et al.
Publicado: (2023)